126 related articles for article (PubMed ID: 38600298)
1. Comparative Effectiveness and Persistence of SB4 and Reference Etanercept in Patients With Psoriatic Arthritis in Norway.
Łosińska K; Pripp AH; Bakland G; Fevang BS; Brekke LK; Wierød A; Korkosz M; Haugeberg G
Arthritis Care Res (Hoboken); 2024 Apr; ():. PubMed ID: 38600298
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Persistence in SB4- and Reference Etanercept-Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway.
Haugeberg G; Bakland G; Rødevand E; Hansen IJW; Diamantopoulos A; Pripp AH
Arthritis Care Res (Hoboken); 2023 Sep; 75(9):1986-1995. PubMed ID: 36722450
[TBL] [Abstract][Full Text] [Related]
3. Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study.
Tweehuysen L; Huiskes VJB; van den Bemt BJF; Vriezekolk JE; Teerenstra S; van den Hoogen FHJ; van den Ende CH; den Broeder AA
Arthritis Rheumatol; 2018 Sep; 70(9):1408-1418. PubMed ID: 29609207
[TBL] [Abstract][Full Text] [Related]
4. Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study.
Pope J; Hall S; Bombardier C; Haraoui B; Jones G; Naik L; Etzel CJ; Ramey DR; Infante R; Miguelez M; Falcao S; Sahakian S; Wu D
Adv Ther; 2022 Nov; 39(11):5259-5273. PubMed ID: 36136243
[TBL] [Abstract][Full Text] [Related]
5. The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases.
Bruni C; Gentileschi S; Pacini G; Baldi C; Capassoni M; Tofani L; Bardelli M; Cometi L; Cantarini L; Nacci F; Vietri M; Bartoli F; Fiori G; Frediani B; Matucci-Cerinic M
Ther Adv Musculoskelet Dis; 2020; 12():1759720X20964031. PubMed ID: 33133246
[TBL] [Abstract][Full Text] [Related]
6. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.
Emery P; Vencovský J; Sylwestrzak A; Leszczynski P; Porawska W; Baranauskaite A; Tseluyko V; Zhdan VM; Stasiuk B; Milasiene R; Barrera Rodriguez AA; Cheong SY; Ghil J
Rheumatology (Oxford); 2017 Dec; 56(12):2093-2101. PubMed ID: 28968793
[TBL] [Abstract][Full Text] [Related]
7. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.
Emery P; Vencovský J; Sylwestrzak A; Leszczyński P; Porawska W; Baranauskaite A; Tseluyko V; Zhdan VM; Stasiuk B; Milasiene R; Barrera Rodriguez AA; Cheong SY; Ghil J
Ann Rheum Dis; 2017 Jan; 76(1):51-57. PubMed ID: 26150601
[TBL] [Abstract][Full Text] [Related]
8. Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review.
Ebbers HC; Pieper B; Issa A; Addison J; Freudensprung U; Rezk MF
Rheumatol Ther; 2019 Sep; 6(3):317-338. PubMed ID: 31385263
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects.
Lee YJ; Shin D; Kim Y; Kang J; Gauliard A; Fuhr R
Br J Clin Pharmacol; 2016 Jul; 82(1):64-73. PubMed ID: 26972584
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness and persistence of reference etanercept versus biosimilar etanercept GP2015 among rheumatoid arthritis patients: A cohort study.
Carballo N; Pérez García C; Grau S; Monfort J; Durán-Jordà X; Echeverría-Esnal D; Ferrández O
Front Pharmacol; 2022; 13():980832. PubMed ID: 36263118
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis - A comparison in a real-world national cohort.
Codreanu C; Popescu CC; Mogoșan C; Enache L; Daia S; Ionescu R; Opriș-Belinski D
Biologicals; 2019 Nov; 62():27-32. PubMed ID: 31668853
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4.
Emery P; Vencovský J; Sylwestrzak A; Leszczyński P; Porawska W; Stasiuk B; Hilt J; Mosterova Z; Cheong SY; Ghil J
Ann Rheum Dis; 2017 Aug; 76(12):1986-91. PubMed ID: 28794078
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost-savings.
Deakin CT; Littlejohn GO; Griffiths H; Ciciriello S; O'Sullivan C; Smith T; Youssef P; Bird P;
Intern Med J; 2024 May; 54(5):795-801. PubMed ID: 38009675
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study.
Bonifati C; De Felice C; Lora V; Morrone A; Graceffa D
J Dermatolog Treat; 2020 Nov; 31(7):687-691. PubMed ID: 30985223
[No Abstract] [Full Text] [Related]
15. Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data.
Yoo WH; Kang YM; Kim DW; Kang EH; Lee YA; Suh CH; Sung YK; Lee SH; Gu DH; Lee J; Choe JY
Rheumatol Ther; 2023 Apr; 10(2):329-341. PubMed ID: 36482248
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases.
Kiltz U; Tsiami S; Baraliakos X; Andreica I; Kiefer D; Braun J
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221119593. PubMed ID: 36051634
[TBL] [Abstract][Full Text] [Related]
17. Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study.
Schmalzing M; Kellner H; Askari A; De Toro Santos J; Vazquez Perez-Coleman JC; Foti R; Jeka S; Haraoui B; Allanore Y; Peichl P; Oehri M; Rahman M; Furlan F; Romero E; Hachaichi S; Both C; Brueckmann I; Sheeran T
Adv Ther; 2024 Jan; 41(1):315-330. PubMed ID: 37950790
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study.
Parisi S; Becciolini A; Ditto MC; Rozza D; Zanetti A; Laganà A; Peroni CL; Centanaro Di Vittorio C; Degiovanni R; Realmuto C; Scirè CA; Priora M; Di Donato E; Santilli D; Mozzani F; Lucchini G; Ariani A; Gardelli L; Girelli F; Arrigoni E; Platè I; Bravi E; Paroli M; Caccavale R; Salvarani C; Sandri G; Lumetti F; Volpe A; Marchetta A; Fusaro E
J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35160074
[TBL] [Abstract][Full Text] [Related]
19. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.
Jaworski J; Matucci-Cerinic M; Schulze-Koops H; Buch MH; Kucharz EJ; Allanore Y; Kavanaugh A; Young P; Babic G
Arthritis Res Ther; 2019 May; 21(1):130. PubMed ID: 31138316
[TBL] [Abstract][Full Text] [Related]
20. Etanercept is Effective and Halts Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis: Final Results from a German Non-interventional Study (PRERA).
Wassenberg S; Rau R; Klopsch T; Plenske A; Jobst J; Klaus P; Meng T; Löschmann PA
Rheumatol Ther; 2023 Feb; 10(1):117-133. PubMed ID: 36251174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]